Brixadi: FDA-Approved New Long-Acting Buprenorphine for Opioid Use Disorder
On May 23, 2023: Braeburn announced that FDA has approved Brixadi, the new long-acting formulation of buprenorphine for the opioid use disorder. Now we will…
On May 23, 2023: Braeburn announced that FDA has approved Brixadi, the new long-acting formulation of buprenorphine for the opioid use disorder. Now we will…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.